JPH07101867A - Antacid composition and medicinal composition using the same - Google Patents

Abstract

PURPOSE:To increase the antacid properties and fast-acting properties in an antacid composition. CONSTITUTION:The objective antacid composition contains hydrotalcite and dihydroxyaluminum aminoacetate at a weight ratio of 30/70 to 90/10 as the antacid components. The composition may contain a fast-acting antacid component such as magnesium hydroxide in an amount of 10 to 50wt.%. The composition is useful as a medicinal composition containing the antacid components, carriers, additives, medicines other than the antacid components where the total amount of the antacid components is more than 10wt.%. The medicinal composition is prepared into particles or granules or tableted.

Description

Detailed Description of the Invention

[0001]

FIELD OF THE INVENTION The present invention relates to an antacid composition, and more specifically, it exhibits no effect in patients with low acidity and anoxic acid, and rapidly in patients with hyperacidity. Antacid composition,
The present invention relates to a pharmaceutical composition containing the antacid composition.

[0002]

2. Description of the Related Art Up to now, gastric hyperacidity has been the main cause of burns, postprandial discomfort, bloating, etc., but in recent years, there have been many cases of similar symptoms even in the case of low acid or no acid. It is reported that there is. People with hypoacidity and anoxia
Judging only from subjective symptoms, they often take comprehensive gastrointestinal drugs and antacids. However, in such cases, the symptoms may worsen. Therefore, it is preferable that the effect is not expressed in the patients with hypoacidity and anoxia, and the effect is expressed only in the patients with hyperacidity. Regarding the antacid agent which meets such purpose, for example, JP-A-50-101520
The publication discloses a method of coating an antacid component with a coating agent which dissolves at a pH of 5 to 6 or less. In addition, JP-A-59
JP-A-210012 describes an antacid coated with a coating that is soluble only in the acidic region.

However, in these antacids, polymers used as coating agents such as polyvinyl acetal diethylaminoacetate (manufactured by Sankyo Co., Ltd., trade name AEA), dimethylaminoethylmethacrylate-
Methacrylate copolymer (trade name Eudragit E, manufactured by Rohm Pharma GmbH (Germany)) is expensive. In addition, organic solvents (eg alcohol, acetone, methylene chloride, etc.) are used for coating the coating agent.
Therefore, there are problems of safety and residual solvent.

[0004]

Therefore, an object of the present invention is to dissolve gastric acid in an acidic region to neutralize gastric acid and to increase pH in a neutral region without using a polymer or an organic solvent as a coating agent. An object is to provide an antacid composition and a pharmaceutical composition that can be suppressed.

Another object of the present invention is to provide an antacid composition and a pharmaceutical composition which can adjust the pH to a neutral region rapidly with a simple composition.

Still another object of the present invention is to provide an antacid composition and a pharmaceutical composition capable of rapidly neutralizing gastric acid.

[0007] Another object of the present invention is to provide an antacid composition and a pharmaceutical composition which can be rapidly neutralized in an acidic region and can maintain a neutral region regardless of liquidity.

[0008]

Means for Solving the Problems As a result of intensive studies to achieve the above-mentioned object, the inventors of the present invention effectively used hydrotalcite and dihydroxyaluminum aminoacetate as antacid components, respectively. It has been found that, even though the acidity does not develop, a combination of the two exhibits high anti-acidity and fast-acting properties, and the addition of a fast-acting antacid component such as magnesium hydroxide further improves the above properties. The present invention has been completed.

That is, the antacid composition and the pharmaceutical composition of the present invention contain hydrotalcite and dihydroxyaluminum aminoacetate as antacid components.

In the present specification, a composition composed of an antacid component is referred to as an "antacid composition", and the antacid composition and the medicinal components other than the antacid component, additives, etc. The composition containing the above-mentioned components is collectively referred to as "pharmaceutical composition" including the antacid.

Hydrotalcite as an antacid component belongs to a basic carbonate of magnesium and has a characteristic that it has a long-lasting effect on antacid. The hydrotalcite may be either natural or synthetic hydrotalcite. Preferred hydrotalcites include synthetic hydrotalcites. Synthetic hydrotalcite is commercially available, for example, under the trade name Alkamak (Kyowa Chemical Co., Ltd.).

A typical hydrotalcite has a composition formula M
It is represented by g ₆ Al ₂ (OH) ₁₆ CO ₃ , and at least a part of Al may be substituted with another metal such as Fe.
Hydrotalcite may be used as a mixture of hydrotalcite containing Al and hydrotalcite containing a metal such as Fe in the above composition formula.

Dihydroxyaluminum aminoacetate as an antacid component has a characteristic that the antacid action continues. Dihydroxyaluminum aminoacetate is commercially available, for example, under the trade name of glycinal (Kyowa Chemical Co., Ltd.).

Even if hydrotalcite and dihydroxyaluminum aminoacetate are used alone, both antacid and fast-acting properties cannot be achieved. However, by using both in combination, high antacid and fast-acting properties are obtained. An antacid composition is obtained. The ratio of hydrotalcite and dihydroxyaluminum aminoacetate can be selected within a range that does not impair the antacid property and the fast-acting property. For example, the former / the latter = 30/70 to 90/10 (weight ratio), preferably 40/60. ˜80 / 20 (weight ratio), more preferably 45/55 to 70/30 (weight ratio).

The antacid composition preferably further contains a fast-acting antacid component as an antacid component. The fast-acting antacid component includes, for example, magnesium hydroxide, magnesium oxide, magnesium carbonate, sodium carbonate, sodium hydrogen carbonate and the like. These fast-acting antacid components can be used alone or in combination of two or more.

Preferred fast-acting antacid components include magnesium hydroxide. Magnesium hydroxide is, for example,
It is commercially available under the product name Kyowa Suimag (Kyowa Chemical Co., Ltd.).

Although the desired function is not exhibited even if the fast-acting antacid component is used alone, the combination of the fast-acting antacid component and the antacid component can further improve the antacid and fast-acting properties. The content of the fast-acting antacid component can be selected within a range in which the fast-acting effect is not impaired, and, for example, 10 to 50 in the total amount of the antacid component.
The amount is about 15 to 45% by weight, preferably about 20 to 40% by weight.

The antacid composition of the present invention may contain other antacid components, such as aluminum hydroxide gel, if necessary.
Aluminum-based antacids such as aluminum hydroxide, aluminum silicate, magnesium metasilicate aluminate, magnesium silicate and aluminum sulfate, calcium-based antacids such as calcium hydroxide, magnesium-based antacids such as magnesium silicate It may also contain agents, aminoacetic acid and the like.

The antacid component such as hydrotalcite, dihydroxyaluminum aminoacetate, and fast-acting antacid component is usually used in the form of powder, particularly powder.

The antacid composition of the present invention dissolves in an acidic region to neutralize gastric acid, has an action of suppressing an increase in pH in a neutral region, and is taken by a patient with low acidity and anoxic acidity. However, the antacid is difficult to dissolve in the stomach, and when taken by patients with hyperacidity, it has a feature that it quickly elutes to neutralize excess acid and effectively develop antacid. .

As described above, since the antacid composition of the present invention has high antacid and fast-acting properties, it is useful as a pharmaceutical composition. The pharmaceutical composition may be an antacid containing additives and the like in addition to the above antacid composition, and is a drug containing medicinal components other than antacid components such as digestive agents and analgesics. May be.

Examples of the additives include conventional ingredients such as lactose, corn starch, talc, crystalline cellulose (such as Avicel), powdered sugar, magnesium stearate,
Mannitol, light anhydrous silicic acid, calcium carbonate, L-
Excipients such as cysteine; binders such as starch, pregelatinized starch, sucrose, gelatin, gum arabic powder, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, pullulan and dextrin; Carboxymethylcellulose calcium (eg ECG
505, etc.), low-substituted hydroxypropylcellulose, croscarmellose sodium (eg, Acdisol, etc.), and other disintegrants; anionic surfactant, nonionic surfactant (eg, Pluronic F68, etc.), etc. Mucosal protective agents such as sucralfate;
Lipids (eg higher fatty acids such as stearic acid, higher alcohols such as stearyl alcohol, fatty acid glycerin esters, oils and fats such as hydrogenated cottonseed oil, hydrogenated castor oil, hydrogenated soybean oil, waxes such as carnauba wax and microcrystalline wax) Coloring agents; corrigents and flavoring agents; adsorbents; preservatives; wetting agents; antistatic agents; disintegration extenders and the like.

[0023] Of the above additives, excipients and binders are frequently used as carriers for formulation, and disintegrants are often used. The amount of the additive, particularly the carrier, used is, for example, 10 to 70% by weight, preferably 15 to 6% by weight with respect to the entire composition.
It is 5% by weight, more preferably about 20 to 60% by weight.

In the pharmaceutical composition, the types of medicinal components other than the antacid component are not particularly limited, and include not only human medicine but also animal medicine. Examples of the medicinal component other than the antacid component include digestive agents such as digestive agents, stomachic agents, peptic ulcer agents, and intestinal agents, and may be crude drugs. The antacid composition is often used in combination with a gastrointestinal drug such as a digestive agent, a stomachic agent, and a peptic ulcer agent. These digestive system drugs may be used alone or in combination of two or more.

As the digestive agent, for example, diastase,
Examples include starch digestive enzymes such as puchialin and amylase, protein digestive enzymes such as pepsin, trypsin, and papain, fat digestive enzymes (lipase), pancreatin, limonade hydrochloride, ursodesoxycholic acid, and bile powder. Examples of the stomachic agent include betaine hydrochloride, glutamate hydrochloride, 1-menthol, carnitine chloride, dry yeast and the like, and examples of the peptic ulcer agent include:
Examples thereof include sodium azulene sulfonate, aldioxa, L-glutamine, potassium potassium chlorophyllin, methylmethionine sulfonium chloride, dimethylpolysiloxane and the like. The intestinal rectifying agent includes, for example, a component of live intestinal bacterium.

The herbal medicines include, for example, fungal extract, cinnamomi cortex, magnoliae c
ortex), ginger (zingiberis rhizoma), rhubarb (atractylodis lanceae rhizoma), rhubarb (rhei rh
izoma), clove (caryophylli flos), cock (auranti
i nobilis pericarpium), carrot (ginseng radix),
Red sprout (mallotus japonicus), Oat (phellodendri)
cortex), assembly (swertia japonica), engosaku (C
orydalis tuber), licorice (glycyrrhizae radix), peony (paeonia lactiflora), gentian (Gentianae
radix), Ryutan (Gentianae scabrae radix), Coptidis rhizoma, Spruce (Aurantii pericarp)
ium), fennel (Foeniculi fructus), salamander (Z
anthoxyli fructus) and the like.

The content of the medicinal component other than the antacid component can be appropriately selected according to the kind thereof, and is, for example, 0.001 to 50% by weight, preferably 0.01 to 50% by weight based on the whole composition. 40% by weight, more preferably 0.1-35
It is about% by weight.

In the above-mentioned pharmaceutical composition, the content of each antacid component and the total amount of the antacid composition can be selected within a wide range as long as it is an effective amount. In the pharmaceutical composition, the total amount of the antacid composition composed of hydrotalcite and dihydroxyaluminum aminoacetate is, for example, 5 to 80% by weight, preferably 10 to 10% by weight, based on the entire pharmaceutical composition.
It is about 60% by weight, more preferably about 20 to 50% by weight. Furthermore, in the pharmaceutical composition, the content of the fast-acting antacid component is, for example, 2 to 30 with respect to the entire pharmaceutical composition.
It is about 5% by weight, preferably about 5 to 25% by weight. The content of magnesium hydroxide, which is a preferable fast-acting antacid component, in the pharmaceutical composition is, for example, about 5 to 30% by weight, preferably about 7 to 25% by weight.

In a pharmaceutical composition, hydrotalcite,
The total amount of the antacid composition composed of dihydroxyaluminum aminoacetate and the fast-acting antacid component is, for example, 10% by weight or more, preferably 20 to 70% by weight, and more preferably 25% by weight based on the whole pharmaceutical composition. It is about 60% by weight.

The form of the pharmaceutical composition is not particularly limited, and it may be a powdery mixture containing the above-mentioned antacid composition, an additive and, if necessary, a medicinal component, but it is formulated. preferable. The preparation includes granules (for example, fine granules, granules, powders, pills, etc.) containing the antacid composition and medicinal components and additives other than the antacid component, the powdery mixture and the granules. Solid preparations such as tablets obtained by tableting a composition containing granules and the like, and capsules in which the granules or the like are filled or encapsulated in capsules are included. The preparations are often fine granules, granules, tablets and the like.

The average particle size of the fine granules is, for example, 1
The average particle size of the granules is, for example, 300 to 150.
It is 0 μm, preferably about 500 to 1500 μm.

The preparation containing the antacid composition can be prepared by a conventional method depending on its form. For example, the antacid composition, an additive, and optionally a medicinal component other than the antacid component, a conventional method, for example, extrusion granulation, fluidized granulation, spray granulation, tumbling granulation The preparation can be prepared by a method such as. In the granulation, either a dry granulation method or a wet granulation method can be adopted. In the wet granulation method, a highly safe solvent (for example, alcohol such as ethanol or water) or a solvent solution of the binder is used. Is often used.

[0033]

EFFECTS OF THE INVENTION The antacid composition and the pharmaceutical composition of the present invention have a simple composition without coating, and dissolve in an acidic region to neutralize gastric acid, and increase in pH in a neutral region. Can be suppressed. Further, a composition further containing a fast-acting antacid component can rapidly neutralize stomach acid.

[0034]

EXAMPLES The present invention will be described in more detail based on the following examples.

Example 1 550 g of synthetic hydrotalcite, 550 g of dihydroxyaluminum aminoacetate, 5 of magnesium hydroxide
50 g, lactose 1000 g, corn starch 585 g, crystalline cellulose 40 g, carboxymethyl cellulose calcium (ECG505) 20 g were uniformly mixed, and 900 ml of an aqueous solution containing 5 g of Pluronic F68 was used,
Wet kneading was carried out according to a conventional method.

The kneaded product was passed through a 0.8 mmφ screen of an extrusion granulator (manufactured by Kikusui Seisakusho Co., Ltd .; RG-C125), and then a marumerizer (manufactured by Fuji Paudal Co., Ltd .; QJ).
-230) was used to prepare spherical granules and dried.

The antacid activity of the obtained granules was measured by the following Fuchs' modified method test, which is widely used in the antacid activity test as a test method for granules.

(1) Test with acidic solution While stirring 50 ml of 0.1N hydrochloric acid, 1 g of the sample was heated at a temperature of 3
Add at 7 ° C., and after 10 minutes, add 0.1N hydrochloric acid at a rate of 2 ml per minute. During the above test, the temperature of the test solution is kept at 37 ° C. and the pH is continuously measured.

(2) Test with Purified Water While stirring purified water, 1 g of a sample was added at a temperature of 37 ° C.,
The pH is measured continuously.

The results are shown in FIGS. 1 and 2. 1 and 2
As is clear from the above, in the test with the acidic liquid, neutralization was possible in about 10 minutes, and the duration in the region of pH 3 to 6 was about 52 minutes, and in the test with the purified water, it was maintained at pH 7.8. . Therefore, it is possible to rapidly neutralize in the acidic region and suppress the rise in pH in the neutral region.

Example 2 The antacid activity of the mixed powder of 250 mg of synthetic hydrotalcite and 250 mg of dihydroxyaluminum aminoacetate was measured in the same manner as in Example 1. Table 1 and FIG.
And the results shown in FIG. 4 were obtained.

The amount of each antacid component used is an amount corresponding to an antacid power of 120 ml. In addition, in the table, the test result with the acidic liquid is the measured value after 10 minutes, and the test result with the purified water is the measured value after 30 minutes.

As is apparent from FIGS. 3 and 4, in the test using the acidic solution, the neutralization can be performed in about 10 minutes, and the duration in the pH range of 3 to 6 is about 40 minutes. In the test using the purified water, It persisted at pH 7.8. Therefore, it is possible to rapidly neutralize in the acidic region and suppress the rise in pH in the neutral region.

Comparative Examples 1 to 3 In the same manner as in Example 1 except that synthetic hydrotalcite (Comparative Example 1), dihydroxyaluminum aminoacetate (Comparative Example 2) and magnesium hydroxide (Comparative Example 3) were used alone. Antacid activity was measured. The results are shown in Table 1 together with the results of Examples 1 and 2 above.

The amount of each antacid component used is an amount corresponding to an antacid power of 140 ml. Further, in Table 1, the test results with the acidic liquid are the measured values after 10 minutes, and the test results with the purified water are the measured values after 30 minutes.

[0046]

[Table 1] As is clear from Table 1, even if the synthetic hydrotalcite (Comparative Example 1) and magnesium hydroxide (Comparative Example 3) were used alone, the pH increase was large in the test with purified water and the neutral range was maintained. Is difficult. In addition, dihydroxyaluminum aminoacetate (Comparative Example 2) shows relatively good results with respect to pH stability, but lacks rapid effect.

Example 3 660 g of synthetic hydrotalcite, 495 g of dihydroxyaluminum aminoacetate, 4 of magnesium hydroxide
95 g, lactose 700 g, low-substituted hydroxypropyl cellulose 170 g, corn starch 300 g, and acdisol (croscarmellose sodium) 90 g were added to a vertical granulator (manufactured by Paulec Co., Ltd .; VG-1).
0), and 90 g of hydroxypropylcellulose was dissolved in 700 ml of water to perform wet granulation,
The granules were obtained by sizing with a power mill (P-3 manufactured by Showa Kagaku Kikai Co., Ltd.) and drying.

To the obtained granules, 150 g of carboxymethyl cellulose calcium (ECG505) and 9 g of magnesium stearate were added, mixed with a tumbler mixer (manufactured by Showa Kagaku Kikai KK; TM-15) for 5 minutes, and then rotary tablets. Machine (Kikusui Seisakusho Co., Ltd .; 19
K), tablets (diameter 10 mmφ, 500 mg /
Tablets) were prepared.

Then, the antacid activity was measured in the same manner as in Example 1 using a tablet in an amount corresponding to an antacid power of 140 ml. (1) In the test with an acidic solution, the pH after 10 minutes
Is 6.0, (2) in the test with purified water, p after 30 minutes
H was 7.9, and the pH could be maintained in the neutral range regardless of the liquidity.

Example 4 732 g of synthetic hydrotalcite, 294 g of dihydroxyaluminum aminoacetate, and magnesium hydroxide 4
41 g, dried Chinpi extract 150 g, powdered soup 20
g, Koboku extract powder 17g, Ginger root powder 100
g, clove powder 30 g, dl-carnitine chloride 300
g, licorice powder 150 g, D-sorbitol 1600
g, 80 g of light anhydrous silicic acid (Cyloid 266), 50 g of lactose, and 40 g of hydroxypropyl cellulose (Vergical Granulator, manufactured by Paulec Co., Ltd .; VG-
25), mixed with an alcohol solution in which 16 g of 1-menthol was dissolved, granulated, and dried using a vacuum dryer (Kusuki Seisakusho). The dried granulated product was sized using a power mill (P-3, manufactured by Showa Kagaku Kikai Co., Ltd.).
The fine granules thus obtained contained 732 mg of synthetic hydrotalcite, 294 mg of dihydroxyaluminum aminoacetate and 441 mg of magnesium hydroxide per 3 packs, which corresponds to an antacid power of 420 ml.

When the antacid activity was measured in the same manner as in Example 1, the results shown in FIGS. 5 and 6 were obtained. Figure 5
As is clear from FIG. 6 and FIG.
It could be neutralized in about 10 minutes, the duration in the region of pH 3 to 6 was about 40 minutes, and in the test with purified water, it was maintained at pH 7.9. Therefore, it is possible to rapidly neutralize in the acidic region and suppress the rise in pH in the neutral region.

Example 5 In a kneader (manufactured by Hata Tekko Co., Ltd.), 450 g of a powder of synthetic aluminum silicate and 25 g of a powder of light anhydrous silicic acid were charged, and 450 g of dl-carnitine chloride was added to water 700.
A solution dissolved in ml was added and adsorbed on the powder. This was dried with a vacuum dryer (manufactured by Tachibana Seisakusho) and then pulverized using an atomizer (manufactured by Fuji Paudal; KII-2) to prepare an adsorption powder.

925 g of the adsorbed powder, 700 g of synthetic hydrotalcite (VF), 450 g of magnesium hydroxide, 300 g of dihydroxyaluminum aminoacetate (aluminum glycinate), 150 g of licorice powder, 150 g of chimpi dry extract, 200 g of soup nut powder, and 20 g of konjac dry extract. , Ginger powder 100 g, clove powder 30 g, D-sorbitol 1000 g, mannitol 74 g and hydroxypropyl cellulose (HPC)
80 g was charged in a vertical granulator (manufactured by Paulec Co., Ltd .; FM-G25) and mixed, and then 1-
An alcohol solution in which 16 g of menthol was dissolved was added for granulation. Next, fluidized bed dryer (manufactured by Paulec Co., Ltd .; F
D5S) and dried. After drying, 5 g of light anhydrous silicic acid was added and mixed as a fluidizing agent to the sieved product to obtain 4200 g of granules.

Example 6 350 g of a powder of synthetic aluminum silicate and 30 g of a powder of light anhydrous silicic acid were charged into a kneader (made by Hata Tekko Co., Ltd.), and 450 g of dl-carnitine chloride was added to water 240.
A solution dissolved in ml was added and adsorbed on the powder.
This was dried with a vacuum dryer (manufactured by Tachibana Seisakusho) and then pulverized using an atomizer (manufactured by Fuji Paudal; KII-2) to prepare an adsorption powder.

830 g of the adsorbed powder, light anhydrous silicic acid 49.
5 g, synthetic hydrotalcite (VF) 700 g, magnesium hydroxide 450 g, dihydroxyaluminum aminoacetate (aluminum glycinate) 300 g,
125 g of licorice powder, 150 g of dried chimpi extract, 60 g of succulent powder, 20 g of dried extract of koboku, 10 g of ginger powder, 30 g of clove powder, 99.5 g of croscarmellose sodium (acdizol), mannitol 7
4g and HPC-L (Hydroxypropyl cellulose-L) 120g high speed mixer (Fukae Kogyo)
Was used for granulation. After drying this with a flow coater (Freund), Power Mill (Showa Kagaku Kikai KK; P
-3S). The sized powder was perfumed with alcohol using 13 g of 1-menthol dissolved therein. This sized powder 30
19g magnesium stearate (lubricant) on 31g
And croscarmellose sodium (Acdisol) 1
00 g was added and mixed with a tumbler mixer (Showa Kagaku Kikai Co., Ltd .; TM-15), and a rotary tablet machine (Kikusui Seisakusho Co., Ltd .; Collect 19k) equipped with a punch having a 9.5 mmφ normal surface was mixed. To obtain tablets.

[Brief description of drawings]

FIG. 1 is a graph showing the test results with an acidic liquid in Example 1.

FIG. 2 is a graph showing test results with purified water in Example 1.

FIG. 3 is a graph showing test results with an acidic liquid in Example 2.

FIG. 4 is a graph showing test results with purified water in Example 2.

FIG. 5 is a graph showing test results with an acidic liquid in Example 4.

FIG. 6 is a graph showing test results with purified water in Example 4.

─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. ⁶ Identification code Internal reference number FI technical display area A61K 31:19 33:08)

Claims (24)

[Claims] 1. An antacid composition containing hydrotalcite and dihydroxyaluminum aminoacetate as an antacid component. 2. The ratio of hydrotalcite and dihydroxyaluminum aminoacetate is the former / the latter = 30.
The antacid composition according to claim 1, which is / 70 to 90/10 (weight ratio). 3. The ratio of hydrotalcite and dihydroxyaluminum aminoacetate is the former / the latter = 40.
The antacid composition according to claim 1, which is / 60 to 80/20 (weight ratio). 4. Hydrotalcite is a composition formula Mg ₆ Al
The antacid composition according to claim 1, which is a basic carbonate of magnesium represented by ₂ (OH) ₁₆ CO ₃ . 5. The antacid composition according to claim 1, further comprising a fast-acting antacid component as the antacid component. 6. The antacid composition according to claim 5, wherein the fast-acting antacid component is at least one selected from the group consisting of magnesium hydroxide, magnesium oxide, magnesium carbonate, sodium carbonate and sodium hydrogen carbonate. 7. The antacid composition according to claim 5, wherein the fast-acting antacid component is magnesium hydroxide. 8. The fast-acting antacid component is 1 in the total amount of the antacid component.
The antacid composition according to claim 5, comprising 0 to 50% by weight. 9. The total amount of hydrotalcite and dihydroxyaluminum aminoacetate is 55 to 85% by weight, and magnesium hydroxide, magnesium oxide, magnesium carbonate, sodium carbonate or sodium hydrogen carbonate, based on the whole antacid composition. 15-45% by weight of at least one fast-acting antacid component selected from the group consisting of
And the ratio of the hydrotalcite to the dihydroxyaluminum aminoacetate is the former / the latter =
An antacid composition which is 40/60 to 80/20 (weight ratio). 10. A total amount of hydrotalcite and dihydroxyaluminum aminoacetate of 60 to 80% by weight, and magnesium hydroxide of 20 to 40% by weight, based on the entire antacid composition. Antacid composition. 11. A pharmaceutical composition comprising the antacid composition according to claim 1. 12. The pharmaceutical composition according to claim 11, wherein the total amount of hydrotalcite and dihydroxyaluminum aminoacetate is 5 to 80% by weight based on the total weight of the composition. 13. The pharmaceutical composition according to claim 11, which contains hydrotalcite, dihydroxyaluminum aminoacetate and a fast-acting antacid component in a total amount of 10% by weight or more based on the entire composition. 14. The pharmaceutical composition according to claim 13, wherein the content of the fast-acting antacid component is 2 to 30% by weight based on the whole composition. 15. The pharmaceutical composition according to claim 13, which contains 5 to 30% by weight of magnesium hydroxide based on the whole composition. 16. The pharmaceutical composition according to claim 11, which comprises hydrotalcite, dihydroxyaluminum aminoacetate, a fast-acting antacid component, and an additive. 17. A total amount of hydrotalcite and dihydroxyaluminum aminoacetate of 10 to 60% by weight, a fast-acting antacid component of 5 to 25% by weight, and an additive of 15 to 65% by weight, based on the entire composition, The pharmaceutical composition according to claim 16, wherein the weight ratio of hydrotalcite and dihydroxyaluminum aminoacetate is the former / the latter = 40/60 to 80/20. 18. The pharmaceutical composition according to claim 16, wherein the total amount of hydrotalcite, dihydroxyaluminum aminoacetate and fast-acting antacid component is 20 to 70% by weight based on the total weight of the composition. 19. The pharmaceutical composition according to claim 16, which contains 7 to 25% by weight of magnesium hydroxide as a fast-acting antacid component with respect to the entire composition. 20. The pharmaceutical composition according to claim 16, which further contains a medicinal component other than the antacid component. 21. The pharmaceutical composition according to claim 20, wherein the medicinal component other than the antacid component is a digestive system drug. 22. A medicinal component other than an antacid component is a digestive agent,
The pharmaceutical composition according to claim 20, which is at least one selected from the group consisting of a stomachic agent, a peptic ulcer agent and an intestinal rectifying agent. 23. At least one additive 20 to 60 selected from 0.001 to 50% by weight of a medicinal component other than an antacid component, an excipient, a binder and a disintegrant, based on the entire composition.
21. The pharmaceutical composition according to claim 20, comprising wt%. 24. The pharmaceutical composition according to claim 11, which is a fine granule, a granule or a tablet.